Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people do notice they sweat more in the early weeks of Wegovy. It is not one of the medicine's listed common side effects, but a handful of mechanisms (including the nausea-driven hot flushes, the body's response to rapid metabolic change, and occasional low blood sugar) can all affect how much you perspire. Wegovy (semaglutide) is a prescription-only medicine; whether it is suitable for you is a decision made with a prescriber, not on the basis of a side-effect list alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When semaglutide slows gastric emptying (one of the ways it reduces appetite) a significant minority of users experience nausea, particularly after dose increases. Nausea activates the autonomic nervous system in a way that mimics mild heat stress: blood is redirected, the skin flushes, and you sweat. It is the same reason people break into a cold sweat before being sick. So if you are asking whether semaglutide makes you sweat, the more precise answer is often: nausea makes you sweat, and semaglutide can cause nausea, especially early on.
This pattern tends to be most noticeable on the first one or two doses at a new level, then fades as your digestive system adapts. The NHS medicines page for semaglutide lists the full profile of GI-related effects, which are the same pathway driving this indirect sweating. Understanding how Wegovy affects your appetite and eating helps put all of these early-treatment sensations in context.
If the nausea itself is severe, tell your prescriber. Eating smaller, lower-fat meals and staying well-hydrated can blunt it. A question our prescribers hear regularly: is it safe to keep taking the pen if I felt terrible after the last one? The honest answer depends on the specifics, which is why clinical follow-up exists.
Semaglutide lowers blood glucose, and in rare cases (particularly if someone is eating very little or combining it with other glucose-lowering medicines) blood sugar can drop enough to trigger the classic hypoglycaemia response: cold sweats, shakiness, pallor. In people without diabetes taking Wegovy purely for weight management this is uncommon but not impossible, especially at higher maintenance doses.
Night sweats specifically deserve a mention. Some users report waking damp in the first few weeks. This can reflect the overnight fast interacting with reduced calorie intake and the medicine's glucose effects. It can also reflect hormonal changes that come with significant weight loss itself — something the full Wegovy overview covers in more depth. Neither explanation is alarming on its own, but consistent night sweats warrant a conversation with your prescriber rather than just pushing through.
If you are also finding that your hunger patterns feel unusual, it is worth reading about hunger changes on Wegovy, because disrupted eating schedules can amplify these metabolic signals.
Most extra sweating on Wegovy is transient, mild, and tied to the GI or metabolic adjustment period. A few patterns are different. Profuse sweating combined with severe, persistent stomach pain that radiates to the back can indicate pancreatitis, the MHRA's January 2026 Drug Safety Update flagged acute pancreatitis as a known but infrequent risk with GLP-1 medicines. That combination needs urgent medical attention, not a wait-and-see approach.
Sweating alongside a pounding heart, confusion or extreme fatigue may suggest a more significant blood-sugar or cardiovascular event. These are not reasons to avoid treatment; they are reasons to know what to watch for. You can report suspected side effects at any stage through the MHRA Yellow Card scheme, which also accepts reports about suspect products.
For most people the practical decision is simpler: is the sweating tied to nausea (manageable), to a specific time of day or dose timing (adjustable), or arriving without any obvious trigger (worth flagging)? Tracking it briefly in a notes app for a week makes that conversation with your prescriber much more productive. Our FAQs page covers other common questions about managing treatment day to day.
A few adjustments help while you assess what is going on. Timing your injection on a day when you can rest for a few hours afterward (not, say, the morning of a big presentation or the Friday before a bank holiday when your prescriber is harder to reach) gives you a cleaner read on how your body responds. Stay hydrated; dehydration worsens both nausea and the flushing response. Wear breathable fabrics during the adaptation weeks.
If you are also navigating what to eat alongside treatment, a sample meal plan for semaglutide users is a useful starting point. Smaller, protein-forward meals reduce gastric stress and may indirectly reduce the nausea-sweating cycle. The guide to eating on Wegovy goes into more detail on which foods sit well at each dose stage. Getting this right matters more than most people expect.
If you are considering starting Wegovy and want to understand the full picture before committing, a free consultation with our prescribers is the right first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.